Stock News

Theravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International Conference
South Africa's Aspen sells Australian prescription portfolio to Mylan
Mylan to Host Investor Day on July 31, 2019 in New York City
Mylan and Biocon to Present Final Overall Survival Data for Ogivri™ (trastuzumab-dkst), a biosimilar to Herceptin®, at the American Society of Clinical Oncology (ASCO) Annual Meeting
Mylan's stock falls toward 7 1/2-year low; credit rating now in danger of downgrade to 'junk' at Fitch
Mylan Reiterates 2019 Revenue Guidance for These Segments
Teva, 19 other drug companies accused of inflating drug prices

As seen on...